Navigation Links
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
Date:9/20/2011

orporate governance were essential to building the company's long-term shareholder value and sustainable success. Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc., and as Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc.

Clark A. Johnson, who has been a director of Neurologix since February 2004, stepped down as Vice Chairman, President and CEO upon Mr. Adams's and Mr. Koven's arrivals. Martin J. Kaplitt, M.D., who was a founder and has been a member of the Board since November 1999, relinquished his position as Board Chairman upon Mr. Adams's assumption of such role. Both Mr. Johnson and Dr. Kaplitt will remain on the Board of Directors.  

"We thank Clark for his leadership of Neurologix and his successful stewardship of NLX-P101 as the Company completed the first successful Phase 2 study of a gene therapy product for Parkinson's disease," said Dr. Kaplitt. "We are excited and hopeful that the experienced leadership provided by Mr. Adams and Mr. Koven will help Neurologix secure the additional financing needed to carry out the Company's planned operations and business activities as we continue to pursue new and, potentially, exciting milestones in the development of gene therapy treatments for patients in urgent need."

About Neurologix

Neurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are l
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurologix Announces Second Quarter 2011 Financial Results
2. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
3. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Creabilis Appoints Dr David Roblin as Chief Medical Officer
6. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
9. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Fuel Cells (SOFCs) - Global Strategic Business Report" report ... worldwide markets for Solid Oxide Fuel Cells (SOFCs) in US$ ... Canada , Europe , ... estimates and forecasts are provided for the period 2012 through ...
Breaking Biology Technology:Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... Tectonics Corporation,s (Amex: ETC ) ("ETC" or ... of two BARA-MED(R)XD Monoplace hyperbaric oxygen chambers in the ... state-of-the-art monoplace chambers are the first computer-controlled hyperbaric chambers ... , Hyperbaric oxygen (HBO) ...
... REYKJAVIK, Iceland, Dec. 8 deCODE genetics,(Nasdaq: ... an international consortium of,scientists from deCODE and major ... variation in the human genome (SNP) that is ... type 2 diabetes (T2D). deCODE,will employ its CLIA-registered ...
... NVAX ) today announced that the Company will hold ... human clinical trial in,healthy adult subjects of Novavax,s seasonal influenza ... 2008. , The call ... Rahul Singhvi and other members of senior management, including Chief,Medical ...
Cached Biology Technology:Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 2Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 3Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 4deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service 2deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service 3deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service 4Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008 2
(Date:8/21/2014)... of radiations in the 3.3 to 4.4 nanometre range, ... tissues. New theoretical findings show that it is possible ... could be the basis of an optimal technique to ... to be used in high-precision spectroscopy. Now, a new ... generate the harmonic radiationswhich are multiples of an incoming ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
Breaking Biology News(10 mins):Water window imaging opportunity 2Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... cousin of the humble mustard plant, scientists at the ... big surprise while investigating how plants respond to attacks ... "Contrary to what we thought we'd find, our experiments ... concert with one another in tug-of war or teeter ...
... statistical method is a more reliable way to map ... potential cancer treatment targets, according to new Brown University ... a promising new tool for tracing human gene connections, ... other diseases. Results appeared this week in the online ...
... the humble mustard plant, scientists at the University of ... while investigating how plants respond to attacks from disease ... what we thought we'd find, our experiments showed that ... one another in tug-of war or teeter totter-fashion to ...
Cached Biology News:FDA approves more generic AIDS drugs 2FDA approves more generic AIDS drugs 3Researchers develop promising new gene network analysis method 2UNC plant researchers discover proteins interact to form hair-trigger protection against invaders 2UNC plant researchers discover proteins interact to form hair-trigger protection against invaders 3
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
LAB/Probe Mouse-Rabbit DAB Kit...
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
G-protein coupled purinergic receptor P2Y8...
Biology Products: